Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

Lipodystrophy Clinical Trial

Official title:

Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05419037
• Other study ID #: 10000757
• Secondary ID: 000757-DK
• Status: Recruiting
• Start date: September 7, 2022
• Est. completion date: March 1, 2025

Study information

• Verified date: April 24, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Megan S Startzell, R.N.
• Phone: (301) 402-6371
• Email: megan.startzell[@]nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background: Lipodystrophy is a health problem in which the body does not have enough fat tissue. People with lipodystrophy may not make enough of the hormone leptin. Leptin regulates hunger. Low leptin levels trigger hunger. People with lipodystrophy can have many health problems. They may take a drug (metreleptin) that mimics leptin. Little is known about how taking metreleptin may affect a pregnancy. Metreleptin may be helpful or harmful to pregnant women. It may also affect the health of the child who is born. Objective: This natural history study will collect data about the effects of taking metreleptin while pregnant. Eligibility: Women aged 18 years or older with lipodystrophy who have been pregnant. Women who did and who did not take metreleptin during their pregnancies are needed. Children of women with lipodystrophy who took this drug during pregnancy are also needed. Design: Participants will have 1 study visit. This visit may be by phone, by telehealth, or in-person. Participants will answer questions about their pregnancies. They will discuss any health problems they had. They will be asked about any medicines they took before and during their pregnancies. They will be asked about the health of their children. Participants medical records will be reviewed. Participants may need to provide a blood sample. They may also be asked to provide a sample of breastmilk. Participants children may also be asked to provide a blood sample....

Description:

Study Description: Single-site cross-sectional study of women with lipodystrophy who had pregnancies during which they were or were not exposed to metreleptin, and the offspring of women whose offspring were exposed to metreleptin during pregnancy. The study involves secondary use of data and samples from other studies in which these subjects participated, review of outside medical records, and collection of a single blood specimen if a biobanked specimen is not available. The hypotheses are: 1. Pregnancy complications will be less prevalent and severe in women with lipodystrophy who took metreleptin during pregnancy compared to those who did not, due the beneficial effects of metreleptin on metabolic complications of lipodystrophy. 2. Anti-leptin antibodies may be detected in some offspring born to women with lipodystrophy treated with metreleptin during pregnancy, but these antibodies will not be associated with adverse health outcomes. Objectives: Primary: Determine pregnancy outcomes, including type and frequency of pregnancy complications in women treated with metreleptin during pregnancy vs. untreated pregnancies. Secondary: Determine if anti-leptin antibodies are detectable in offspring of women treated with metreleptin during pregnancy. Endpoints: Primary Endpoint: We will quantify a set of pregnancy and offspring outcomes and complications. Secondary Endpoints: Frequency and type of anti-leptin antibodies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: March 1, 2025
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 98 Years

Eligibility

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

• Women with lipodystrophy who had pregnancies with or without use of metreleptin:
• Female, aged >= 18 years
• Clinical diagnosis of non-HIV associated generalized or partial lipodystrophy
• History of one or more pregnancies
• Offspring of women with lipodystrophy who had pregnancies while taking metreleptin:
• Males or females aged >=1 month
• Mothers took metreleptin during their pregnancy
• Availability of a biobanked blood specimen or willingness to provide a blood specimen Note that subjects treated with metreleptin during pregnancy may participate in this study regardless of the participation of their offspring. EXCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must not meet any of

the following criteria:

• Inability of subject or guardian to understand or the unwillingness to sign a written informed consent document (except as noted below with *)
• Pregnancy.
• Subjects who otherwise meet inclusion/exclusion criteria but who are not reachable to obtain informed consent may be included under a waiver of consent.

Related Conditions & MeSH terms

• Lipodystrophy

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	type and frequency of pregnancy complications	We will quantify a set of pregnancy and offspring outcomes and complications.	at end of study

External Links

•   NIH Clinical Center Detailed Web Page